Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:IMVT NASDAQ:KNSA NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$20.00-0.4%$20.80$19.00▼$26.58$2.46B0.851.43 million shs1.53 million shsIMVTImmunovant$16.40+0.2%$16.32$12.72▼$32.10$2.85B0.451.38 million shs1.37 million shsKNSAKiniksa Pharmaceuticals International$36.86+0.8%$31.32$17.82▼$36.93$2.71B0.2418,378 shs415,974 shsRAPPRapport Therapeutics$28.03-10.9%$15.42$6.43▼$42.27$1.15B0.73901,701 shs1.71 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.03%-2.48%+1.11%-23.68%+2.45%IMVTImmunovant-4.49%+11.44%+5.89%-2.21%-51.90%KNSAKiniksa Pharmaceuticals International+2.41%+9.20%+13.75%+22.84%+46.69%RAPPRapport Therapeutics+119.15%+78.50%+116.29%+139.13%+54.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$20.00-0.4%$20.80$19.00▼$26.58$2.46B0.851.43 million shs1.53 million shsIMVTImmunovant$16.40+0.2%$16.32$12.72▼$32.10$2.85B0.451.38 million shs1.37 million shsKNSAKiniksa Pharmaceuticals International$36.86+0.8%$31.32$17.82▼$36.93$2.71B0.2418,378 shs415,974 shsRAPPRapport Therapeutics$28.03-10.9%$15.42$6.43▼$42.27$1.15B0.73901,701 shs1.71 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-1.03%-2.48%+1.11%-23.68%+2.45%IMVTImmunovant-4.49%+11.44%+5.89%-2.21%-51.90%KNSAKiniksa Pharmaceuticals International+2.41%+9.20%+13.75%+22.84%+46.69%RAPPRapport Therapeutics+119.15%+78.50%+116.29%+139.13%+54.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$33.2066.00% UpsideIMVTImmunovant 2.83Moderate Buy$33.60104.88% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$41.1711.68% UpsideRAPPRapport Therapeutics 3.00Buy$31.0010.60% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, IMVT, CPRX, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $34.009/4/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/6/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$31.007/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $54.007/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$17.00 ➝ $18.007/21/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold$18.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M4.98$2.44 per share8.21$6.10 per share3.28IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AKNSAKiniksa Pharmaceuticals International$423.24M6.45N/AN/A$6.60 per share5.58RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6512.129.390.8137.36%40.78%35.36%11/5/2025 (Estimated)IMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04921.73147.44N/A0.90%1.05%0.80%11/4/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$2.50N/AN/AN/AN/A-29.99%-28.64%11/6/2025 (Estimated)Latest RAPP, IMVT, CPRX, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/7/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/A7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55IMVTImmunovantN/A12.3212.32KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16RAPPRapport TherapeuticsN/A22.7522.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%IMVTImmunovant47.08%KNSAKiniksa Pharmaceuticals International53.95%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%IMVTImmunovant1.80%KNSAKiniksa Pharmaceuticals International53.48%RAPPRapport Therapeutics13.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableIMVTImmunovant120174.32 million171.18 millionOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableRAPPRapport TherapeuticsN/A36.50 million31.55 millionN/ARAPP, IMVT, CPRX, and KNSA HeadlinesRecent News About These CompaniesRapport Announces Pricing of Public Offering of Common Stock3 hours ago | globenewswire.comRapport rockets on positive trial data for RAP219September 9 at 12:48 PM | thepharmaletter.comTRapport shares double on better-than-expected seizure drug dataSeptember 9 at 7:48 AM | finance.yahoo.comRapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $34.00September 9 at 2:10 AM | americanbankingnews.comRapport Therapeutics stock soars after positive Phase 2a seizure drug resultsSeptember 8 at 11:42 PM | investing.comRapport shares soar after successful mid-stage seizure trialSeptember 8 at 11:42 PM | statnews.comSRapport soars on phase II RAP-219 data in focal onset seizuresSeptember 8 at 11:42 PM | bioworld.comBRapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy PillSeptember 8 at 11:42 PM | biospace.comBRapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028September 8 at 11:42 PM | seekingalpha.comRapport's seizure drug hits in phase 2, sending stock soaringSeptember 8 at 11:42 PM | fiercebiotech.comFRapport Therapeutics Surges After Promising Mid-Stage Seizure Drug TrialSeptember 8 at 11:42 PM | msn.comRapport Catapults Almost 200% After Succeeding In Hard-To-Treat SeizuresSeptember 8 at 11:42 PM | msn.comRapport Announces Proposed Public Offering of Common StockSeptember 8 at 4:18 PM | globenewswire.comRapport Therapeutics Reports Positive Phase 2a Trial ResultsSeptember 8 at 6:30 AM | tipranks.comRapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset SeizuresSeptember 8 at 6:00 AM | globenewswire.com21,873 Shares in Rapport Therapeutics, Inc. $RAPP Bought by Nuveen LLCSeptember 8 at 3:04 AM | marketbeat.comRapport Therapeutics to Host Conference Call for Phase 2a Trial Topline Results of RAP-219 for Drug-Resistant Focal Onset SeizuresSeptember 5, 2025 | quiverquant.comQRapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025September 5, 2025 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Down - What's Next?September 5, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Down 7.8% - Should You Sell?September 4, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Raises Position in Rapport Therapeutics, Inc. $RAPPSeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRAPP, IMVT, CPRX, and KNSA Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$20.00 -0.08 (-0.40%) Closing price 04:00 PM EasternExtended Trading$20.26 +0.25 (+1.28%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Immunovant NASDAQ:IMVT$16.40 +0.03 (+0.18%) Closing price 04:00 PM EasternExtended Trading$16.76 +0.37 (+2.23%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kiniksa Pharmaceuticals International NASDAQ:KNSA$36.86 +0.29 (+0.79%) Closing price 04:00 PM EasternExtended Trading$36.86 +0.01 (+0.01%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Rapport Therapeutics NASDAQ:RAPP$28.03 -3.44 (-10.93%) Closing price 04:00 PM EasternExtended Trading$27.90 -0.13 (-0.46%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
